-+ 0.00%
-+ 0.00%
-+ 0.00%

Structure Therapeutics Announces Aleniglipron Trial Presentations at ObesityWeek 2026

PUBT·10/19/2026 20:22:49
Listen to the news
Structure Therapeutics Announces Aleniglipron Trial Presentations at ObesityWeek 2026
  • Structure Therapeutics will present aleniglipron obesity trial research at ObesityWeek on Nov. 15, 2026, in National Harbor, Maryland.
  • Two posters will cover the ACCESS trials’ dose-ranging effects and an open-label extension in participants with overweight or obesity.
  • Aleniglipron is an investigational, once-daily oral small-molecule GLP-1 receptor agonist being developed for chronic weight management.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Structure Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610191613PRIMZONEFULLFEED9848782) on October 19, 2026, and is solely responsible for the information contained therein.